Found 556472 clinical trials
Sort by:
Study on a Prosthetic Foot With Adjustable Heel Height
Not Applicable
Not yet recruiting
- Conditions
- Lower Limb Amputation Above KneeLower Limb Amputation Below Knee
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Otto Bock France SNC
- Target Recruit Count
- 30
- Registration Number
- NCT07214493
- Locations
- 🇫🇷
CH Cornouaille, Concarneau, France
🇫🇷CHU Grenoble, Échirolles, France
🇫🇷IRR Louis Pierquin, Nancy, France
Effectiveness of Low-Dose Ketamine and Intravenous Lidocaine Vs. Fentanyl for Postoperative Pain for Patients Undergoing Elective Gynecologic Surgery
Not Applicable
Completed
- Conditions
- Postoperative PainPostoperative Nausea and Vomiting
- Interventions
- Drug: Low dose intravenous ketamine
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Dilla University
- Target Recruit Count
- 70
- Registration Number
- NCT07213687
- Locations
- 🇪🇹
Dilla University, Awasa, Snnpr, Ethiopia
Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Neurimmune AG
- Target Recruit Count
- 35
- Registration Number
- NCT07213583
- Locations
- 🇫🇷
Hôpital Henri Mondor, Créteil, France
🇫🇷CHU de Rennes - Hôpital Pontchaillou, Rennes, France
🇫🇷CHU Toulouse - Hôpital Rangueil, Toulouse, France
The Edison System for Treatment of Benign Prostatic Hyperplasia (BPH) Using Histotripsy
Not Applicable
Not yet recruiting
- Conditions
- Benign Prostatic Hyperplasia
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- HistoSonics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT07214675
Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation
Not Applicable
Not yet recruiting
- Conditions
- AML (Acute Myeloid Leukemia)MDS/AMLMDS (Myelodysplastic Syndrome)
- Interventions
- Drug: RIC regimen
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 27
- Registration Number
- NCT07214064
- Locations
- 🇩🇪
University Hospital , Department of Internal Medicine II, Tübingen, Baden-Wurttemberg, Germany
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
Completed
- Conditions
- Cardiovascular Disease
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1385
- Registration Number
- NCT07214857
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Not Applicable
Not yet recruiting
- Conditions
- Metastatic Pancreatic Ductal AdenocarcinomaStage IV Pancreatic Cancer AJCC v8
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 35
- Registration Number
- NCT07214298
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
Not Applicable
Not yet recruiting
- Conditions
- Mild Cognitive Impairment (MCI)Alzheimer's Disease DiagnosisDementia MCI (Mild Cognitive Impairment)Early Stages of Cognitive DeclineAlzheimer's Disease and Related DementiasAlzheimer's Disease DementiaParkinson's DiseaseParkinson's Disease (PD)Parkinson's Disease With Wearing-off Motor FluctuationsDementia (Diagnosis)
- Interventions
- Other: Control - Placebo ComparatorBehavioral: Structured wellness careBiological: Stem Cell Therapy - ExperimentalDevice: Wearable brain-computer interface devices
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Noah Tech, Corp.
- Target Recruit Count
- 600
- Registration Number
- NCT07214974
- Locations
- 🇺🇸
First Presbyterian Church, Palisades Park, New Jersey, United States
A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)
Not Applicable
Not yet recruiting
- Conditions
- Cutaneous T Cell Lymphoma (CTCL)Mycosis FungoidesSezary Syndrome
- Interventions
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 30
- Registration Number
- NCT07213882
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
Not Applicable
Not yet recruiting
- Conditions
- Symptomatic Venous Thromboembolism (VTE)
- Interventions
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 2000
- Registration Number
- NCT07213778